• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Salarius Pharmaceuticals Inc.

    11/18/25 11:53:37 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Salarius Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    79400X503

    (CUSIP Number)


    11/11/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    79400X503


    1Names of Reporting Persons

    CVI Investments, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    362,499.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    362,499.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    362,499.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


    SCHEDULE 13G

    CUSIP No.
    79400X503


    1Names of Reporting Persons

    Heights Capital Management, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    362,499.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    362,499.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    362,499.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Salarius Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    2450 Holcombe Blvd., Suite X, Houston, TX 77021
    Item 2. 
    (a)Name of person filing:

    This statement is filed by the entities listed below, who are collectively referred to herein as "Reporting Persons," with respect to the shares of common stock of Salarius Pharmaceuticals, Inc. (the "Company"), $0.0001 par value per share (the "Shares"). (i) CVI Investments, Inc. (ii) Heights Capital Management, Inc.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of CVI Investments, Inc. is: P.O. Box 309GT Ugland House South Church Street George Town Grand Cayman KY1-1104 Cayman Islands The address of the principal business office of Heights Capital Management, Inc. is: 101 California Street, Suite 3250 San Francisco, California 94111
    (c)Citizenship:

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    79400X503
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this Item 4(a) is set forth in Row 9 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The number of Shares reported as beneficially owned consists of (i) 300,000 Shares, and (ii) Shares issuable upon the exercise of warrants to purchase Shares (the "Warrants"). The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 9.99%. The Company's Prospectus (Registration No. 333-284368), filed on November 12, 2025, indicates there were 3,566,117 Shares outstanding as of the completion of the offering of the Shares referred to therein.
    (b)Percent of class:

    9.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by this Item 4(c)(i) is set forth in Row 5 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    The information required by this Item 4(c)(ii) is set forth in Row 6 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by this Item 4(c)(iii) is set forth in Row 7 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by this Item 4(c)(iv) is set forth in Row 8 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    CVI Investments, Inc.
     
    Signature:/s/ Sarah Travis
    Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary of Heights Capital Management, Inc.
    Date:11/18/2025
     
    Heights Capital Management, Inc.
     
    Signature:/s/ Sarah Travis
    Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary
    Date:11/18/2025

    Comments accompanying signature:  Heights Capital Management, Inc. serves as authorized agent of CVI Investments, Inc. pursuant to a Limited Power of Attorney, a copy of which is attached as Exhibit 24 hereto.
    Exhibit Information

    EXHIBIT INDEX EXHIBIT DESCRIPTION ________ ________ 24 Limited Power of Attorney 99 Joint Filing Agreement

    Get the next $SLRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLRX

    DatePrice TargetRatingAnalyst
    3/11/2022$5.00 → $4.00Buy
    HC Wainwright & Co.
    8/25/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Salarius Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $5.00 previously

    3/11/22 6:32:47 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Salarius Pharmaceuticals with a new price target

    HC Wainwright & Co. initiated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $5.00

    8/25/21 6:10:11 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Exec VP Finance, CFO Rosenblum Mark J bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 11,299% to 20,177 units (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/20/25 4:42:09 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Exec VP Finance, CFO Rosenblum Mark J bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 11,299% to 20,177 units (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/20/25 4:42:09 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Arthur David J.

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    4/12/24 4:50:27 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Rosenblum Mark J

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    2/22/24 4:37:10 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRX
    SEC Filings

    View All

    Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

    11/19/25 4:05:16 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Salarius Pharmaceuticals Inc.

    SCHEDULE 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

    11/18/25 11:53:37 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

    11/17/25 5:23:58 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX"

    HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under the stock ticker "SLRX." S&P CapIQ inaccurately characterized the Salarius Pharmaceuticals and Decoy Therapeutics merger and inaccurately stated that the Company had been delisted from the Nasdaq Capital Market. The Company is working to have this inaccurate information corrected. Similar inaccuracies that appeared on Yahoo Finance were corrected earlier this week. On November 13, 2025, Salarius completed an under

    11/19/25 2:42:26 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

    Strategic transaction supports the advancement of Decoy's rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT™ platform Combined company has pro forma cash of $14 million following merger and closing of recent public offering HOUSTON and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals (NASDAQ:SLRX) ("Salarius" or the "Company") and Decoy Therapeutics ("Decoy") announce the completion of their strategic merger with the combined company now focused on advancing Decoy's pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and m

    11/13/25 8:45:00 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Strong Earnings and Biotech Resilience Define the Midweek Momentum

    DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB:KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research consortia across the globe, Kraig Biocraft Laboratories (OTCQB:KBLB) appears poised to crack biotechnology's most persistent challenge: scalable, high-performance recombinant spider silk. Kraig's imminent shipments of spider silk fiber and fabric samples to fashion and performance textile partners signal a watershed moment. Unlike fermentation-based methods that have frustrated even DuPont, BASF, and Bolt Threads, Kraig's innovation lies in reprogramming silkworms themselves to spi

    11/12/25 11:00:36 AM ET
    $CRMD
    $HUMA
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SLRX
    Leadership Updates

    Live Leadership Updates

    View All

    Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

    CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t

    4/16/25 8:00:00 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

    HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has been named Director of the Company's new targeted protein degradation program. In this newly created position, Dr. Santiesteban will assume responsibility for overseeing the development of SP-3164, the program's lead drug candidate, and advancing it into clinical trials. Her appointment immediately follows Salarius' recent strategic expansion into the targeted protein degradation field through its acquisitio

    2/3/22 7:30:00 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRX
    Financials

    Live finance-specific insights

    View All

    Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH

    HOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, will hold a conference call with slides to discuss recent clinical and preclinical data from its lead programs on December 14, 2022 at 11:00 a.m. Eastern time. Management will review recently announced interim results from its ongoing Phase 1/2 trial with seclidemstat in Ewing sarcoma and FET-rearranged sarcomas, as well as new clinical data from MD Anderson Cancer Center's study with seclidemstat plus azacytidine in hematological cancer

    12/8/22 8:00:00 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

    60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who Achieved Confirmed Disease Control HOUSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company's Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment fo

    12/1/22 8:00:00 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

    HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the quarter and recent weeks included: Financial Highlights Cash and equivalents were $22.6 million as of June 30, 2022, compared with $29.2 million as of December 31, 2021Tightly managed expenses while progressing toward multiple near-term milestonesNet loss of $4.7 million, or $0.09 per share, compared with net loss of $3.1 million, or $0.07 per share,

    8/8/22 8:30:00 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc.

    SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

    11/14/24 4:38:31 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Salarius Pharmaceuticals Inc.

    SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

    2/14/24 3:54:30 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

    2/13/23 4:30:18 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care